Considering that SGLT2 gene expression levels are lower than GLUTs in most solid tumors36, and 18F-2-FDG is not a specific substrate of SGLT2, we speculate the use of hypoglycemic SGLT2 inhibitors would be more beneficial in 18F-FDG PET diagnosis than insulin for most patients with hyperglycemia combined with tumors. This evidence concerns the gene SLC5A2 and Hyperglycemia.